| Autor: |
Gaba P; Thrombolysis in Myocardial Infarction Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts, USA., Rosenson RS; Division of Cardiovascular Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA., López JAG; Global Development, Amgen Inc, Thousand Oaks, California, USA., Watts GF; Department of Cardiology, Royal Perth Hospital, Perth, Western Australia, Australia., Leucker TM; Department of Cardiology, Johns Hopkins, Baltimore, Maryland, USA., Kuder JF; Thrombolysis in Myocardial Infarction Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts, USA., Im K; Thrombolysis in Myocardial Infarction Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts, USA., Kassahun H; Global Development, Amgen Inc, Thousand Oaks, California, USA., Wang H; Global Development, Amgen Inc, Thousand Oaks, California, USA., Wu Y; Global Development, Amgen Inc, Thousand Oaks, California, USA., Wang J; Global Development, Amgen Inc, Thousand Oaks, California, USA., Ohman EM; Global Development, Amgen Inc, Thousand Oaks, California, USA., Sabatine MS; Thrombolysis in Myocardial Infarction Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts, USA., O'Donoghue ML; Thrombolysis in Myocardial Infarction Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts, USA. Electronic address: modonoghue@bwh.harvard.edu. |
| Abstrakt: |
Competing Interests: Funding Support and Author Disclosures The OCEAN(a)-DOSE study was supported by Amgen. Dr Rosenson has received research funding to his institution from Amgen, Arrowhead, Lilly, Novartis, and Regeneron; has received consulting fees from Amgen, Arrowhead, Avilar Therapeutics, CRISPR Therapeutics, Editas, Lilly, Lipigon, Novartis, New Amsterdam, Precision Biosciences, Regeneron, and Verve Therapeutics; has received royalties from Wolters Kluwer; has stock holdings in MediMergent, LLC; and has pending patents on analytical methods and systems for biocellular marker and detection using microfluidic profiling (PCT/US2019/026364) and compositions and methods relating to the identification and treatment of immunothrombotic conditions. Dr López is an employees and shareholder of Amgen Inc. Dr Watts has received research grants, travel support for symposia, fees for lectures or honoraria for advisory boards from Amgen, Novartis, Sanofi, Silence Therapeutics, Esperion, Novo Nordisk, Pfizer, Arrowhead, CSL Sequirus, and AstraZeneca. Dr Leucker has received research grant support from Amgen and Merck. Ms Kuder and Dr Im are members of the TIMI Study Group, which has received institutional research grant support through Brigham and Women’s Hospital from Abbott, Amgen, Anthos Therapeutics, AstraZeneca, Bayer HealthCare Pharmaceuticals, Inc, Daiichi-Sankyo, Eisai, Intarcia, MedImmune, Merck, Novartis, Pfizer, Quark Pharmaceuticals, Regeneron Pharmaceuticals, Inc, Roche, Siemens Healthcare Diagnostics, Inc, The Medicines Company, and Zora Biosciences. Drs Kassahun, Wang, Wu, and Ohman are employees and shareholders of Amgen Inc. Dr Sabatine has received research grant support through Brigham and Women’s Hospital from Abbott, Amgen, Anthos Therapeutics, AstraZeneca, Daiichi-Sankyo, Eisai, Intarcia, Ionis, The Medicines Company, MedImmune, Merck, Novartis, and Pfizer; has been a consultant for Althera, Amgen, Anthos Therapeutics, AstraZeneca, Beren Therapeutics, Bristol Myers Squibb, Fibrogen, Intarcia, Merck, Moderna, Novo Nordisk, and Silence Therapeutics; and is a member of the TIMI Study Group, which has also received institutional research grant support through Brigham and Women’s Hospital from ARCA Biopharma, Inc, Janssen Research and Development, LLC, Siemens Healthcare Diagnostics, Inc, Softcell Medical Limited, Regeneron, Roche, and Zora Biosciences. Dr O’Donoghue has received grant funding via Brigham and Women’s Hospital from Amgen, Novartis, AstraZeneca, Janssen, Intarcia, and GlaxoSmithKline; and has received consulting fees from Amgen, Novartis, AstraZeneca, and Janssen. Dr Gaba has reported that she has no relationships relevant to the contents of this paper to disclose. |
